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ABSTRACT 
Introduction: Pathological complete remission of liver metastases is a rare colon cancer treatment outcome with in-
creased 5-year survival of 76%. Case Report: Metastatic colorectal cancer patient with pathological complete remis-
sion of large hepatic metastasis after palliative chemotherapy in combination with bevacizumab is presented. Solitary 
liver metastasis measuring 8 cm was observed in computed tomography (CT) scan before combined treatment. The best 
radiological response during treatment with FOLFOX-4 and bevacizumab therapy was partial remission and patient 
underwent partial hepatectomy. Since the operation material was free of viable adenocarcinoma cells the effect of 
FOLFOX-4 in combination with bevacizumab treatment was interpreted as the pathological complete remission. Con-
clusion: Use of combination chemotherapy and targeted therapy with the aim to reduce initially unresectable liver me-
tastasis is the best option to achieve complete pathological remission and significantly prolong survival. 
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1. Introduction 
There are about 410,000 new cases of colorectal cancer 
in Europe every year. Most of patients with colorectal 
cancer (CRC) are over 65 years of age and the disease is 
rare before the age of 45 (2 per 100,000/year). Approxi- 
mately 25% present with metastases at initial diagnosis 
and almost 50% of patients with CRC will develop me- 
tastases, contributing to the high mortality rates reported 
for metastatic colorectal cancer (mCRC) [1]. Despite 
recent advances in the medical treatment of mCRC, 
which include oxaliplatin- and irinotecan-based first-line 
regimens and the increasing use of targeted monoclonal 
antibodies, survival rates for patients with mCRC remain 
unacceptably low [2]. The standard of care is palliative 
chemotherapy in order to prolong overall survival and 
control symptoms. 
About 13% of patients with initially unresectable me- 
tastases can become resectable after multidrug chemo- 
therapy [3], that can improve progression free and overall 
survival: 5-year survival rates are in the range of 21% to 
58% in patients with colorectal cancer liver metastases 
after surgical resection [4]. 
Among all patients who underwent liver metastasis 
resection, 4% present a rare clinically significant situa- 
tion—pathological complete remission (pCR), a com- 
plete absence of residual cancer cells on examination by 
a pathologist [5]. More recently, the addition of mono- 
clonal antibodies (bevacizumab or cetuximab) to cytotoxic 
chemotherapy has increased the rate of tumor response, 
suggesting that the addition of these agents could im- 
prove resectability rate [5,6]. Patients who achieve patho- 
logical complete remission, which is most often defined 
as the complete disappearance of cancer cells in the tu- 
mor area after preoperative therapy, have a better prog- 
nosis than those who do not [6]. In recent years, several 
studies have been performed to find markers to predict 
the probability of patients achieving pathologic complete 
remission, including routine clinical and pathological 
characteristics, biomarkers, gene expression profiling and 
imaging techniques [6,7]. Because of there has been rela- 
tively small account of prospective randomized trials, the 
gold standard to predict a response to preoperative ther- 
apy is still missing. 
The objective of the research is to analyze the results 
of a clinical case and to identify possible predictive and 
prognostic factors which might affect treatment outcome. 
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2. Case Report 
Thirty five-year-old man was urgently hospitalized at 
surgical department of District Hospital with clinically 
diagnosed bowel obstruction and has undergone Hart- 
mann’s type resection of distal descendent colon (sigma). 
The patient reported a 1-year history of constipation and 
abdominal pain but did not receive any treatment before 
presentation. Whereas during the operation was found 
malignancy it was decided to continue diagnostic proce- 
dures and treatment in University hospital with experi- 
ence in colorectal cancer management. 
Patient was hospitalized at Pauls Stradins Clinical 
University Hospital Oncology Clinic. Abdominal com- 
puted tomography (CT) scan showed a large unresectable 
solitary liver metastasis in right lobe (segment 8) with 8 
cm as the largest diameter (Figure 1). A chest CT scan 
showed no evidence of lung metastases, and the cardiac, 
mediastinal, pleural, and bony structures were normal. 
Carcinoembryonic antigen (CEA) level was 4.2 ng/ml—a 
normal reference is 0.0 - 5.0 ng/ml. Results of a complete 
blood count, plasma levels of electrolytes, tests of co- 
agulation and kidney and liver function, and a urinalysis 
were normal. The patient’s family has no cancer history. 
Poorly differentiated adenocarcinoma that invades 
through the muscularis propria into the subserosa and 
metastases in 7 regional lymph nodes were found in op- 
eration material corresponding to pT3N2bG3R0. Immu- 
nohistochemical staining was positive for CK20 and 
CDX2 and negative for TP53 staining. Proliferation frac- 
tion by Ki-67 protein expression was 73%. Immunohis- 
 
 
tochemical analysis of two mismatch-repair genes’ 
(MSH2 and MSH6) products showed isolated loss of 
nuclear MSH6 immunoreactivity, suggesting loss-of- 
function mutation in the MSH6 gene. As the isolated loss 
of nuclear immunoreactivity for MSH6 in the tumor in- 
dicates for a putative germline mutation [8], the MSH6 
gene was sequenced but no clinically significant germ- 
line mutation was found. Tumor tissue was checked for 
predominant somatic mutation (KRAS 12th, 13th and 
61st codons, BRAF V600E, TP53 5th - 8th exons, 
PIK3CA 9th and 10th exons and PTEN whole coding 
region) and only one mutation G61H in the KRAS gene 
was found. 
It was decided to initiate neoadjuvant chemotherapy 
with FOLFOX4/bevacizumab to make initially unre- 
sectable hepatic colon cancer metastasis resectable. The 
patient received eight infusions of neoadjuvant chemo- 
therapy with FOLFOX-4 and four infusions of bevaci- 
zumab every 2 weeks at 4-month period. The mild sen- 
sory peripheral neuropathy, grade 1 neuthropenia and 
grade 1 hepatotoxicity was observed during treatment 
period. 
Control CT scan showed partial remission—the tumor 
was decreased by 50% with 4 cm in greatest dimension 
(Figure 1). Neoadjuvant chemotherapy plus biological 
agent turned initially unresectable metastasis resectable, 
and patient became eligible for potentially curative sur- 
gery. The patient underwent a partial hepatectomy (re- 
section of segment 8). Intraoperative ultrasonography 
(IOUS) during surgery excluded additional liver metas- 
tases. The cut-surface of the resected specimen from S8 
showed a homogenous yellow-white mass. The size of 
solitary lesion, as described in the gross pathology report, 
was 3.4 cm by 2.3 cm. Microscopically, most of the 
specimen were replaced with necrotic tissue and granu- 
lomatous inflammation. Shadows of cytokeratin 20- 
positive and CDX2-positive cells were found in the ne- 
crosis. The operation material was free of viable adeno- 
carcinoma cells. Since no viable tumor cells were ob- 
served in any of the whole sections of the resected 
specimen, entirely submitted for microscopic evaluation, 
the effect of FOLFOX-4 in combination with bevacizu- 
mab treatment on the metastatic colon cancer was inter- 
preted as the pathological complete remission. 
The patient recovered from surgery without any com- 
plications, completed additional four infusions of post- 
operative FOLFOX-4 chemotherapy. At this moment, 14 
months since hepatic surgery, the examinations showed 
no evidence of disease. 
Figure 1. CT scans before (a), (b) and after (c), (d) neoad- 
juvant treatment. Solitary large initially unresectable liver 
metastasis marked with arrow heads in right lobe is seen (a), 
(b). After FOLFOX plus bevacizumab treatment the liver 
metastasis was reduced in size by 50%. Radiological partial 
response of metastasis marked with arrow heads can be 
seen on CT scan (c), (d). The operation material revealed 
pathological complete remission. 
3. Discussion 
This case report shows a complete pathological remission 
in primary metastatic colorectal cancer patient with un- 
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favorable prognosis and a small chance to recovery. In a 
recent study the probability of complete pathological 
response is described based on four predictive factors in 
patients treated with preoperative chemotherapy—age < 
60 years, size < 3 cm, preoperative CEA < 30 ng/ml, 
objective radiological response [6]. According to these 
data the patient had 10% probability of pCR of liver me- 
tastasis. In this study, the pCR of liver metastases in pa- 
tients after resection was associated with a 5-year overall 
survival rate of 76% compared to 45% in patients with- 
out a pCR. 
There are published many clinical factors to predict 
outcome after resection of colorectal liver metastases— 
nodal status, disease-free interval from the primary to 
discovery of the liver metastases, number of metastases, 
preoperative CEA level, size of the metastases. Regard- 
ing to the clinical risk score the patient’s prognosis is 
calculated with 5-year survival rate of 20% [9]. In spite 
of unfavorable clinical factors the complete pathological 
remission of liver metastasis was achieved which signifi- 
cantly improves the patient’s prognosis. 
In our case the mutations shown in cancer cells aren’t 
clinically significant. None of driver mutations (KRAS, 
BRAF, PTEN, TP53 and PIK3CA) was found. It is 
tempting to speculate that the good treatment results are 
due to lack of any clinically relevant mutation combined 
with the young age, single liver lesion, normal CEA level 
and loss of MSH6 staining in cancer tissue. DNA mis- 
match repair dysfunction could change response to 
treatment DNA damaging agents. Several studies have 
shown that defects in mismatch repair genes result in 
increased cisplatin but not oxaliplatin resistance [10]. 
Due to wild-type BRAF and KRAS in cancer tissue, 
initially it was considered to use an anti-EGFR mono- 
clonal antibody cetuximab according to guidelines [1]. 
The first reason why it was decided in favor of anti- 
VEGF antibody bevacizumab was the fact that it in com- 
bination with oxaliplatin-based regimen chemotherapy 
increase the rates of radical liver surgery [5,6], and the 
second one—was controversial role of the G61H muta- 
tion in the KRAS gene on resistance to cetuximab [11]. 
Costs of medication were taken into account. It should be 
noted that standard palliative chemotherapy in Latvia is 
oxaliplatin or irinotecan containing regiments, but mono- 
clonal antibodies are not reimbursed. 
The prediction of a complete pathological response of 
metastases after multidrug chemotherapy is important, 
but it is quite difficult, since there is no clear correlation 
between a pathological response and a radiological re- 
sponse. That patient contrast enhanced CT scan revealed 
partial radiological response with tumor shrinkage by 
50% after chemotherapy. It must be noted that total ne- 
crosis of tumor cells does not imply disappearance of 
metastasis in pre-operative imaging and does not neces- 
sarily correspond to radiological complete remission 
[6,7]. By contrast, a complete radiological response is not 
always associated with a complete pathologic response 
[12]. 
4. Conclusion 
Metastatic colorectal cancer is potentially fatal disease 
with short survival. Use of combination chemotherapy 
plus targeted therapy with the aim to reduce initially un- 
resectable liver metastasis is the only option to achieve 
complete pathological remission and significantly pro- 
long survival. 
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